China Race On For New Wave Of Novel Drugs

Govt Providing Support

A new drug-hunting initiative funded by the Chinese government will focus on novel therapies for chronic diseases and encourage academia-industry collaboration.

fast followers
The Chinese government has kickstarted a new round of national drug-hunting race. • Source: Shutterstock

The Chinese government has kickstarted a new round of a national drug hunting campaign involving the industry and academia, with the first two programs in lung and breast cancer launched this month.

Key Takeaways
  • A new China government R&D support program will focus on four major chronic disease areas with high prevalence in China – cardiovascular, respiratory and metabolic diseases and malignant tumors.

Th fresh state-supported effort will be focused primarily on four major chronic conditions with a high prevalence in China –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By 

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?